TrialAnnals of hematology2025

Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.

Austin Kulasekararaj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.